We are delighted to announce a significant settlement in Jazz Pharmaceuticals' dispute with Avadel, resolving multi-front litigation over Jazz's oxybate franchise for narcolepsy treatment.
Avadel had pursued more than $1 billion in antitrust damages, alleging that Jazz improperly listed a patent in the FDA's Orange Book to block market entry, whilst simultaneously asserting trade secret misappropriation and patent infringement claims. All claims have now been dismissed.
This result caps a series of decisive victories: a jury trial win in March 2024, a successful injunction in August 2024, and a successful appellate defence in May 2025. The settlement includes substantial royalty payments extending through 2036, providing Jazz with significant long-term commercial certainty.
Led by Partner Nick Cerrito, this outcome was achieved by a formidable cross-office team: steig d. olson, Will Sears, Gabe Brier, Frank Calvosa, Ellyde Thompson, Nicholas LoCastro, William Price, Joseph Paunovich, Andrew Chalson, and Christopher D. Porter, Evangeline Shih, alongside associates / Of Counsel: Nic Siebert, Lynette Lim, Max Hawley, John Galanek, Quentin Jorgensen, Shira Bergman, Marielle Paloma Greenblatt, Kevin Adams, Shivani Arimilli, Kate Dolbear, Aslesha Parchure, Elizabeth Murphy, Carolina Yu, and many others.
Congratulations to everyone who contributed to this outstanding result.